A family office/venture capital firm based in New York firm manages an evergreen fund that seeks to make seed, venture, and growth equity investments in early to mid-stage medical device companies, but will also consider secured debt to help revenue generating companies with short term cash flow issues. The firm will also consider pre-seed investments. The firm can allocate anywhere from $1M to $10M per company, but generally allocates around $8M. The firm typically does 3 rounds of financing with an initial investment of around $3M. The firm is geographically agnostic, but highly prefers to invest in companies that are based in the US. The firm seeks to make about 3-4 allocations in the next 6-9 months.

The firm is currently looking for medical device companies with a strong emphasis on products with a 510(k) regulatory pathway. In terms of subsectors, the firm is looking for products specifically in the areas of interventional radiology and cardiology, spine/orthopedics and minimally invasive surgery. The firm is generally opportunistic in terms of indication.

The firm is looking to invest in companies with a management team with a track record of success in the healthcare industry. However, the firm is generally flexible and does not require a full management team. The firm can assemble the management team over the course of the investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An angel network focused on social impact investing with chapters throughout the United States is currently looking for investments in healthcare. The group typically participates in seed and series A raises of $300,000-$1.5 million, but may take part in raises of up to $3 million. In general the group only considers opportunities in the USA and Canada, but the group will also consider global health companies located in the developing world.

The Group is open to opportunities in several industries, including healthcare technologies. The group does not invest in biotech drug development, but is interested in medical technology companies with lower capital requirements and a shorter path to commercialization. The group generally invests in companies that have completed product development and have a product on the market. The group is particularly interested in global health companies that are developing last-mile solutions for delivering healthcare in the developing world. Companies developing a product that is not regulated by the FDA, including consumer health, healthcare IT and lab equipment/lab software companies are more likely to be of interest.

The group typically invests in companies that have revenues, or which can demonstrate user traction among free users eg. via a successful trial or partnership.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A large pharma group based in the US is looking to form partnerships with development stage biotech companies via a variety of structures, including strategic venture investments, in-licensing, collaborations, and M&A. The firm is actively pursuing these opportunities and is willing to look globally.

The firm focuses on therapeutic assets in oncology (including immuno-oncology), immunology, and neurodegenerative diseases.  The firm is also interested in fibrotic diseases of the liver (such as HBV). The firm is open to both biologic and small molecule opportunities, but is generally not focused on cell therapies such as CAR-T technologies. The firm will consider assets at any stage of development, but is particularly interested in outreach from companies developing early stage technologies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate investment group that invests strategically on behalf of a large medtech firm uses a variety of structures to work with early stage medical technology companies, including both licensing relationships and equity investments on a case by case basis. The firm is a flexible investor, and the firm’s allocation sizes are wide ranging. The firm invests worldwide.

The firm invests in sectors that are relevant to its parent companies business groups including Cardiovascular, Restorative Therapies (including spinal implants, neuromodulation treatments for pain and urological disorders, deep brain stimulation, and neurovascular devices), Diabetes, and Minimally Invasive Therapies (including general surgery, gastrointestinal care, pulmonology, and respiratory care and monitoring technologies). The firm is interested in diversifying the firms product and services offerings within all of these four Groups and also in integrating new fields of information technology and services into the strategic areas, such as IT-enabled patient monitoring and contract management of provider facilities. The firm invests at a range of development stages but generally prefers to work with companies that have obtained clinical data regarding their asset.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture fund/family office founded in 2002 and based in the southern USA manages two venture funds, in addition to a number of private capital accounts through which investments are made. The firm looks to make equity investments generally in series A and B rounds of approximately $1.0 – $1.5 million in rounds totaling $3-$7 million. The firm is open to investing into companies located throughout the United States and makes approximately 2-4 new investments per year.

Within life sciences, the firm is most interested in companies in the medical device and diagnostics space. The firm is looking for companies that have a 510k regulatory pathway with at least a working prototype of the product and preferably some in-human data. The firm is generally open to all indications with particular interested in oncology, rare cancers, diabetes, neurology, ophthalmology and cardiology. The firm is especially interested in CLIA lab diagnostics, software enabled devices, molecular diagnostics for rare cancers and diseases, and algorithms that interpret genetic information and recommend treatment options. The firm is also interested in nutraceuticals, expedited drug development, HIT and business to business technology companies although these areas are less of a focus.

The firm is looking for private companies with experienced management team and looks to take a board seat following investment. The firm looks to be a hands on investor and is willing to both lead and co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital fund financed entirely by a Russian pharmaceutical company is looking to make investments ranging from $5-$15 million in companies in the life science space. The firm could make as many as 2-3 investment over the next 6-9 months and is willing to allocate to companies located around the globe. Besides equity investment, the firm would consider local licensing opportunities for Russian/CIS market.

The fund is currently looking for companies developing therapeutics and is open to both small molecules, biologics, and cell/gene therapy. The firm is more interested in companies working with single assets although they are also willing to consider platform technologies. Indications of interest include Oncology, Inflammation, Neurodegenerative diseases, Orphan genetic diseases, Critical care, Regenerative medicine and Autoimmune diseases. The firm looks for companies that have at least reached in-vivo proof of concept with their lead asset.

The fund is looking for privately held companies and prefers companies with experienced management teams in place. The firm looks to act as a value-added investor through their strategic alignment with its parent company, and looks to take a seat on the company’s board on a case by case basis. The firm is willing to both lead and co-invest in financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Hong Kong has approximately USD 1 billion AUM and has raised 3 funds to date. The firm’s third fund was closed at USD 100 million in 2014. The firm makes early stage investments, typically in series A and B at USD 2-10 million, in the TMT and healthcare sector. The firm’s primary geographic focus is China and Asia, with a growing interest in cross-border opportunities in the US and EU.

In healthcare, the firm is interested in healthcare services, medical devices, early stage therapeutics, and specialty pharma. Within medical devices, the firm seeks growth stage products from MRI to IVD. Within therapeutics, the firm considers both small molecules and biologics. The firm is opportunistic in terms of subsectors and indications. The firm is interested in post-angel stage companies with products that are in pre-clinical or early clinical trials. Later stage opportunities can also be considered.

The firm seeks a strong and experienced management team and could act as lead investor or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com